Skip to Content



PDF options:  View Fullscreen   Download PDF

PDF Transcript

Hepatect® CP 50 IU/ml solution for infusion

Human hepatitis B immunoglobulin for intravenous administration
Read all of this leaflet carefully before you start using this medicine because
it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others.
It may harm them, even if their signs of illness are the same as yours.
- If you get any of the side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Hepatect CP is and what it is used for
2. What you need to know before you use Hepatect CP
3. How to use Hepatect CP
4. Possible side-effects
5. How to store Hepatect CP
6. Contents of the pack and other information

185968 005

1. What Hepatect CP is and what it is used for
Hepatect CP contains the active ingredient human hepatitis B immunoglobulin, which can protect you from hepatitis B. Hepatitis B is an inflammation
of the liver caused by the hepatitis B virus. Hepatect CP is a solution for infusion (into a vein) and comes in vials containing 2 ml (100 International Units
[IU]), 10 ml (500 IU), 40 ml (2000 IU) and 100 ml (5000 IU).
Hepatect CP is used to give immediate and long-term immunity (protection) to:
- prevent hepatitis B infection in patients who have not been vaccinated
or fully vaccinated against hepatitis B and who are at risk of infection with
hepatitis B.
- prevent infection of a transplanted liver in patients who test positive for
hepatitis B.
- newborn babies whose mothers are infected with the hepatitis B virus.
- protect patients for whom hepatitis B vaccination has not provided adequate protection.

185.968.005.s.1_10.indd 1

2. What you need to know before you use Hepatect CP
Do not use Hepatect CP:
- if you are allergic to human immunoglobulin or any of the other ingredients of
this medicine (listed in section 6). An allergic reaction may include rash, itching,
difficulty breathing or swelling of the face, lips, throat or tongue.
- if you have already been fully vaccinated against hepatitis B and you are immune.
Warning and precautions
Talk to your doctor, pharmacist or nurse before using Hepatect CP
- if you suffer from a condition with low antibody levels in your blood (hypo- or
- if you have had a reaction to other antibodies (in rare cases you may be at risk of
allergic reactions)
Your doctor will take special care if you are overweight, elderly, diabetic, or if you
suffer from high blood pressure, low blood volume (hypovolaemia), have an IgA deficiency, have problems with your blood vessels (vascular diseases) or are at risk for
thrombotic events.

The measures taken are considered effective for enveloped viruses such as human
immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus.
The measures taken may be of limited value against non-enveloped viruses such as
hepatitis A virus and parvovirus B19.
Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections possibly because the antibodies against these infections, which are contained in the product, are protective.

Package leaflet: Information for the user

The following information is intended for healthcare professionals only:

This medicinal product must not be mixed with other medicinal products.

Method of administration
Hepatect CP should be infused intravenously at an initial rate of 0.1 ml/kg body
weight/hour for 10 minutes. If well tolerated, the rate of administration may gradually be increased to a maximum of 1 ml/kg body weight/hour.

No other preparations may be added to the Hepatect CP solution as any change in
the electrolyte concentration or the pH may result in precipitation or denaturisation of the proteins.

It is strongly recommended that every time you receive a dose of Hepatect CP the
name and batch number of the medicine are recorded in order to maintain a record
of the batches used.

Clinical experience in newborns of hepatitis B virus carrier mothers has shown, that
Hepatect CP intravenously used at an infusion rate of 2 ml in-between 5 to 15 minutes has been well tolerated.
Special Precautions
Thromboembolic complications have been associated with the use of normal
IVIg. Therefore, caution is recommended especially for patients with thrombotic
risk factors.

Inform your doctor if you have been vaccinated against hepatitis B within the past
four weeks. You may need to be re-vaccinated if you are given Hepatect CP.

Other medicines and Hepatect CP
Tell your doctor if you are taking or have recently taken any other medicines.
Hepatect CP can reduce the effectiveness of some vaccines such as:
- measles
- rubella
- mumps
- chicken pox
You may have to wait up to 3 months before you can have some vaccines.

Please note - reactions
You will be carefully observed during the infusion period with Hepatect CP to make
sure that you do not suffer a reaction. Your doctor will make sure that the rate at
which Hepatect CP is infused is suitable for you.

Effects on blood tests
Hepatect CP can affect blood tests. If you have a blood test after receiving Hepatect CP, please inform the person taking your blood or your doctor that you have
received Hepatect CP.

If you have a reaction during the infusion of Hepatect CP, tell your doctor immediately. The rate of infusion can be slowed or the infusion can be stopped altogether.

Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to
have a baby, ask your doctor for advice before taking this medicine.
Your doctor will decide if Hepatect CP may be used during pregnancy and breastfeeding.

Information on transmission of infectious agents
Hepatect CP is made from human plasma (the liquid part of blood). When medicines are made from human blood or plasma, certain measures are put in place to
prevent infections being passed on to patients.

These include:
• careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded,
• the testing of each donation and pools of plasma for signs of virus/infections,
• the inclusion of steps in the processing of the blood or plasma that can inactivate
or remove viruses.
Despite these measures, when medicines prepared from human blood or plasma
are administered, the possibility of passing on infection cannot be totally excluded.
This also applies to any unknown or emerging viruses or other types of infections.

Driving and using machines
The ability to drive and operate machines may be impaired by some adverse reactions associated with Hepatect CP. Patients who experience adverse reactions
during treatment should wait for these to resolve before driving or operating machines.
3. How to use Hepatect CP
Hepatect CP is intended for intravenous administration (infusion into a vein). It is
given to you by a doctor or nurse. The recommended dose will depend on your condition and your body weight. Your doctor will know the right amount to give you.

Patients should be monitored for serum anti-HBs antibody levels regularly.
Certain severe adverse drug reactions may be related to the rate of infusion. The
recommended infusion rate given under "Method of administration" must be
closely followed. Patients must be closely monitored and carefully observed for any
symptoms throughout the infusion period.
Any infusion-related adverse events should be treated by lowering the infusion rate
or by stopping the infusion.
Hepatect CP contains IgA. Individuals who are deficient in IgA have the potential for
developing IgA antibodies and may have anaphylactic reactions after administration of blood components containing IgA. The physician must therefore weigh the
benefit of treatment with Hepatect CP against the potential risk of hypersensitivity

Instructions for handling and disposal
Do not use Hepatect CP after the expiry date which is stated on the label and outer
The product must be brought to room or body temperature before use.
The solution should be clear or slightly opalescent. Do not use solutions that are
cloudy or have deposits.
The product once opened should be used immediately.
Any unused product or waste material should be disposed of in accordance with
local requirements.
Unless otherwise prescribed, the following recommendations apply:
Prevention of hepatitis B re-infection after liver transplantation for hepatitis B induced liver failure:
In adults:
10 000 IU on the day of transplantation, peri-operatively then 2000-10 000 IU (40200 ml)/day for 7 days, and as necessary to maintain antibody levels above 100150 IU/l in HBV-DNA negative patients and above 500 IU/l in HBV-DNA positive

During graft re-infection preventive therapy very rare cases of intolerance reactions
may be linked to an interval increase between administrations.

In children:
Posology should be adjusted according to body surface area, on the basis of
10 000 IU/1.73 mC.

It is strongly recommended that every time Hepatect CP is administered to a patient, the name and batch number of the product is recorded.

Immunoprophylaxis of hepatitis B:

Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the injection. In case of shock, standard medical treatment for shock should
be implemented.

- Prevention of hepatitis B in case of accidental exposure in non-immunised subjects:
At least 500 IU (10 ml), depending on the intensity of exposure, as soon as possible
after exposure, and preferably within 24 - 72 hours.
25.11.14 10:36

- Prevention of hepatitis B in the newborn, of a hepatitis B virus carrier-mother, at
birth or as soon as possible after birth:
30-100 IU (0.6-2 ml)/kg. The hepatitis B immunoglobulin administration may be
repeated until seroconversion following vaccination.
In all these situations, vaccination against hepatitis B virus is highly recommended.
The first vaccine dose can be injected on the same day as human hepatitis B immunoglobulin, however in different sites.
In subjects who did not show an immune response (no measurable hepatitis B
antibodies) after vaccination, and for whom continuous prevention is necessary,
administration of 500 IU (10 ml) to adults and 8 IU (0.16 ml)/kg to children every
2 months can be considered; a minimum protective antibody titre is considered to
be 10 mIU/mL.

- Immunoprophylaxis of hepatitis B in haemodialysed patients:
8-12 IU (0.16-0.24 ml)/kg with a maximum of 500 IU (10 ml), every 2 months until
seroconversion following vaccination.

At the beginning of your infusion you will receive Hepatect CP at a slow rate. Your
doctor may then gradually increase the infusion rate.

By reporting side effects you can help provide more information on the safety of
this medicine.

If you have any further questions on the use of this product, ask your doctor or

5. How to store Hepatect CP
Keep this medicine out of the sight and reach of children.
Your pharmacist or doctor knows how to store Hepatect CP.
It should be kept in the outer carton to protect it from light.
Hepatect CP should be stored in a refrigerator at 2-8 °C. Do not freeze.

4. Possible side effects
Like all medicines, this medicine can have side effects, although not everybody gets
Rarely, the following may occur:
- chills
- headache
- fever
- vomiting
- malaise (feeling sick)
- nausea (urge to vomit)
- low blood pressure
- allergic reactions
- skin (cutaneous) reactions such as erythema (redness), itching
- tachycardia (faster heart beat)
Very rarely, the following may occur:
- severe allergic reactions (anaphylactic shock)
- joint pain
With human immunoglobulin the following has been observed:
- temporary meningitis (inflammation of the brain lining)
- decrease of red blood cells (reversible haemolytic anaemia/haemolysis)
- an increase in the serum creatinine (a waste product) and/or sudden kidney
- cases of blood clots in the veins (thromboembolic reactions) have been reported
in the elderly, in patients with signs of cerebral or cardiac ischemia, and in overweight and patients with very low blood volume (severely hypovolaemic).
If a side effect occurs, the infusion rate will be decreased or stopped.
Reporting of side effects
If you get any side effects talk to your doctor, pharmacist or nurse. This includes
any side effects not listed in this leaflet. You can also report side effects directly via
Yellow Card Scheme

185.968.005.s.1_10.indd 2

6. Contents of the pack and other information
What Hepatect CP contains:
- The active substance of Hepatect CP is human hepatitis B immunoglobulin for
intravenous administration.
Hepatect CP contains 50 mg/ml of human plasma protein of which at least
96 % is immunoglobulin G (IgG). The content of hepatitis B antibody is 50 IU/ml.
The maximum immunoglobulin A (IgA) content is 2.000 micrograms/ml. The IgG
subclass distribution is approx.
59 % IgG1, 35 % IgG2, 3 % IgG3 and 3 % IgG4.
- The other ingredients are glycine and water for injections.
What Hepatect CP looks like and the contents of the pack
Hepatect CP is a solution for infusion. The solution is clear to faintly opalescent
(milky colours like an opal) and colourless to pale yellow.
Pack containing 1 vial with 100 IU in 2 ml solution
Pack containing 1 vial with 500 IU in 10 ml solution
Pack containing 1 vial with 2000 IU in 40 ml solution
Pack containing 1 vial with 5000 IU in 100 ml solution
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer:
Biotest Pharma GmbH
Landsteinerstrasse 5
63303 Dreieich
Tel.: + 49 6103 801-0
Fax: + 49 6103 801-150
PL 04500/0006
This leaflet was last revised in 12/2014.
25.11.14 10:36

+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.